Epidemiology of Non-Alcoholic Fatty Liver Disease
The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. The prevalence of NAFLD in the general population of Western countries is 20–30%. About 2–3% of the general population is estimated to have non-alcoholic steatohepatitis (NASH), which may progress to liver cirrhosis and hepatocarcinoma. As a rule, the prevalence of NAFLD is higher in males and increases with increasing age, and it is influenced by the diagnostic method and the characteristics of the population, especially lifestyle habits. Population-based studies provide better estimates of the prevalence of NAFLD as compared to autoptic and clinical studies, but few such studies have been performed to date. The diagnosis of NAFLD in population studies is usually obtained by ultrasonography, which is known to underestimate the prevalence of fatty liver. The Dallas Heart Study and the Dionysos Study reported that 30% of the adults in the USA and 25% in Italy have NAFLD. In these studies, 79% and 55% of patients with NAFLD had normal aminotransferase levels, showing that liver enzymes are not surrogate markers of NAFLD in the general population. Noninvasive markers such as the fatty liver index obtained from the Dionysos Study may be useful to screen for NAFLD in the general population. The most important risk factors for NAFLD are male gender, age, obesity, insulin resistance and the cardiometabolic alterations that define the metabolic syndrome. The prevalence of NAFLD is 80–90% in obese adults, 30–50% in patients with diabetes and up to 90% in patients with hyperlipidemia. The prevalence of NAFLD among children is 3–10%, rising up to 40–70% among obese children. Moreover, pediatric NAFLD increased from about 3% a decade ago to 5% today, with a male-to-female ratio of 2:1. The incidence and natural history of NAFLD are still not well defined, but it is recognized that the majority of individuals with NAFLD do not develop NASH. The incidence of NAFLD is probably increasing in Western countries, strictly linked to lifestyle habits.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of NAFLD among normal-weight children is 3–10%, rising up to 40–70% among obese children”
From Lack of Exercise Is a Major Cause of Chronic Diseases (2012) · cites this paper as [33]
Citations
Cites
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352 · cited 1×
“In the literature, many competing definitions of the MS are available. The definition recently put forth by the International Federation for the Study of Diabetes (IDF) [”
BackgroundNonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664 · cited 1×
“It is important to note that this prevalence is partly dependent upon the method used to diagnose FL, the method used to assess alcohol intake and the cutoff point used to exclude ‘relevant’ alcohol intake, see table 2 , with respective references [ , , , , , , , , , , , , , , , , , , , , , ,”
MethodNonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“] and 15p in Asian countries [ , , , , , , , , , ,”
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042 · cited 1×
“We suggest to expand the number of prospective cohort studies in the general population, even if they are more expensive and difficult to handle, because they give more reliable results about the burden of disease attributable to NAFLD. The most simple, noninvasive and practical method for diagnosing FL in population…”
BackgroundSelf-citationLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679 · cited 1×
“Population and clinical studies have increasingly shown that most cases of NAFLD are associated with the metabolic syndrome (MS), so that NAFLD is presently considered the hepatic manifestation of MS [”
BackgroundNonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154 · cited 1×
“Definition and Classification of Non-Alcoholic Fatty Liver DiseaseNon-alcoholic fatty liver disease (NAFLD) is operationally defined as fatty liver (FL), i.e. an accumulation of lipids inside the hepatocytes exceeding 5p of the weight of the liver, without hepatitis B virus or hepatitis C virus infection and in the ab…”
BackgroundIndependent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Angulo, P., Keach, J. C., Batts, K. P., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,610 · cited 1×
“A recent study showed that 27p of US adults have raised levels of liver enzymes and that 79p of these values cannot be explained by the most common causes of liver disease [ , , , , , , , ,”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568 · cited 1×
“While steatosis is usually associated with a benign prognosis, steatohepatitis and fibrosis may progress to cirrhosis and possibly hepatocarcinoma.During the last decade, the number of studies on NAFLD has grown exponentially, and new concepts have been acquired by the scientific community. We now know that NAFLD is o…”
Background
Research works printed but not linked: 7
- 10.1097%2f00005176-200001000-00017 · doi:10.1097/00005176-200001000-00017 · Paper page
- 10.1016%2fs1590-8658%2802%2980194-3 · DOI
- 10.1111%2fj.1572-0241.2001.04052.x · doi:10.1111/j.1572-0241.2001.04052.x · Paper page
- 10.1016%2fs0168-8278%2801%2900094-0 · DOI · Paper page
- 10.1111%2fj.1572-0241.1999.01451.x · doi:10.1111/j.1572-0241.1999.01451.x · Paper page
- 10.3109%2f00365527709181339 · DOI · Paper page
- 10.1053%2fgast.2001.25540 · DOI · Paper page
Cited by
Items 401–500 of 1,000
Alpha-Galacto-Oligosaccharides at Low Dose Improve Liver Steatosis in a High-Fat Diet Mouse Model
Chappuis, E., Morel-Despeisse, F., Bariohay, B., & Roux, J. (2017) · Molecules · doi:10.3390/molecules22101725 · Cited by 34
Pfirrmann, D., Huber, Y., Schattenberg, J. M., & Simon, P. (2019) · Journal of Medical Internet Research · doi:10.2196/11250 · Cited by 35
“Some researchers consider NAFLD as a hepatic manifestation of metabolic syndrome, whereas others consider it a consequence of metabolic syndrome [3,10-13].”
BackgroundAn overview of the genetics, mechanisms and management of NAFLD and ALD
Rowell, R., & Anstee, Q. M. (2015) · Clinical Medicine · doi:10.7861/clinmedicine.15-6-s77 · Cited by 35
Izadi, F., Farrokhzad, A., Tamizifar, B., Tarrahi, M. J., & Entezari, M. H. (2020) · Phytotherapy Research · doi:10.1002/ptr.6826 · Cited by 32
Santos‐Sánchez, G., Cruz‐Chamorro, I., Álvarez‐Ríos, A. I., Fernández-Santos, J. M., Vázquez‐Román, V., Rodríguez-Ortiz, B., Álvarez‐Sánchez, N., Álvarez‐López, A. I., Millán-Linares, M. C., Millán, F., et al. (2021) · Antioxidants · doi:10.3390/antiox10081222 · Cited by 34
“In fact, 80–90% of obese adults present MAFLD [36].”
BackgroundRace/Ethnicity, Obesity, and Related Cardio-Metabolic Risk Factors: A Life-Course Perspective
Wahi, G., & Anand, S. S. (2013) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-013-0329-6 · Cited by 31
Non alcoholic fatty liver disease in Nigerian population with type II diabetes mellitus
Olusanya, T. O., Lesi, O. A., Adeyomoye, A., & Fasanmade, O. A. (2016) · Pan African Medical Journal · doi:10.11604/pamj.2016.24.20.8181 · Cited by 32
“The prevalence of NAFLD among people with Type II Diabetes Mellitus (T2DM) is significantly higher than reported in the general population and ranges from 21%-78% [4,8-10].”
BackgroundQin, L., Zhang, W., YANG, Z. K., Niu, Y., Li, X., Lü, S., Xing, Y., Lin, N., Zhang, H., Ning, G., et al. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0168-4 · Cited by 32
Li, H., Ying, H., Hu, A., Hu, Y., & Li, D. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00942 · Cited by 37
Recurrence of non-viral liver disease after orthotopic liver transplantation
El‐Masry, M., Gilbert, C. P., & Saab, S. (2011) · Liver International · doi:10.1111/j.1478-3231.2010.02434.x · Cited by 33
“NAFLD affects about 20–40% of the population of Western industrialized countries (11, 12).”
BackgroundDeciphering non-alcoholic fatty liver disease through metabolomics
Cano, A., & Alonso, C. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140138 · Cited by 32
Yassin, A. A., Alwani, M. M., Alzubaidi, R. T., Almehmadi, Y., Nettleship, J. E., Al‐Rumaihi, K., Albaba, B., Kelly, D. M., & Saad, F. (2020) · The Aging Male · doi:10.1080/13685538.2020.1867094 · Cited by 34
Ramanujam, V., Amutha, A., Anjana, R. M., Ranjit Unnikrishnan, I., & Mohan, V. (2014) · Endocrine Practice · doi:10.4158/ep14044.or · Cited by 31
Dembek, A., Laggai, S., Kessler, S. M., Czepukojc, B., Simon, Y., Kiemer, A. K., & Hoppstädter, J. (2017) · Immunobiology · doi:10.1016/j.imbio.2017.01.003 · Cited by 32
García‐Jaramillo, M., Lytle, K. A., Spooner, M. H., & Jump, D. Β. (2019) · Metabolites · doi:10.3390/metabo9110252 · Cited by 32
The role of the gut microbiome and exercise in non-alcoholic fatty liver disease
Houttu, V., Boulund, U., Grefhorst, A., Soeters, M. R., Pinto‐Sietsma, S., Nieuwdorp, M., & Holleboom, A. G. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820941745 · Cited by 36
Alavinejad, P., Zakerkish, M., Hajiani, E., Hashemi, S. J., Chobineh, M., & Moghaddam, E. K. (2016) · Journal of Gastroenterology and Hepatology Research · doi:10.17554/j.issn.2224-3992.2016.05.662 · Cited by 32
Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges
Thiagarajan, P., & Aithal, G. P. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.03.002 · Cited by 33
“24%,(17) rising to 66% and 90% in type 2 diabetic and obese populations, respectively.(18) In a large retrospective cohort study involving 646 biopsy-proven patients with NAFLD, the entire group showed a trend towards higher risk for mortality than controls (HR = 1.”
BackgroundCell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma
Udoh, U. S., Rajan, P. K., Nakafuku, Y., Finley, R., & Sanabria, J. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147734 · Cited by 31
“Clinically, NASH is considered when serum aminotransferases are elevated in an obese subject with metabolic syndrome (hypertension and insulin resistance), or with incidental findings on abdominal imaging [4].”
BackgroundEpidemiology and Natural History of Nafld/Epidemiologija I Prirodna Istorija Nealkoholne Masne Jetre
Corte, C. D., Ferrari, F., Villani, A., & Nobili, V. (2014) · Journal of Medical Biochemistry · doi:10.2478/jomb-2014-0049 · Cited by 34
Hao, L., Ito, K., Huang, N. K., Sae‐tan, S., Lambert, J. D., & Ross, A. C. (2014) · Metabolism · doi:10.1016/j.metabol.2014.06.016 · Cited by 30
“Nonalcoholic fatty liver disease (NAFLD) currently affects about one-third of the population in Western countries [1,2] and is an emerging public health problemworldwide.”
Clinical and Virological Characteristics of Chronic Hepatitis B Patients with Hepatic Steatosis
Zheng, R.-D., Chen, J.-N., Zhuang, Q.-Y., Lu, Y., Chen, J., & Chen, B.-F. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.5649 · Cited by 30
Hepatic glucose utilization in hepatic steatosis and obesity
Keramida, G., Hunter, J., & Peters, A. M. (2016) · Bioscience Reports · doi:10.1042/bsr20160381 · Cited by 30
The pharmacological management of NAFLD in children and adolescents
Liyanagedera, S., Williams, R. P., Veraldi, S., Nobili, V., & Mann, J. P. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1365599 · Cited by 32
Alizadeh, A., Mansour‐Ghanaei, F., Roozdar, A., Joukar, F., Sepehrimanesh, M., Hojati, A., & Mansour-Ghanaei, A. (2018) · Journal of Clinical Imaging Science · doi:10.4103/jcis.jcis_93_17 · Cited by 30
“[7] Introduction N onalcoholic fatty liver disease (NAFLD) is one of the most common causes of the elevated liver enzyme in adult and one of the main etiologies of chronic liver disease.[1,2] Pathophysiology of NAFLD is related to the fat infiltration in the liver parenchyma and can be ranged from simple hepatic steat…”
Rosenblatt, R. E., Mehta, A., Snell, D. B., Hissong, E. M., Kierans, A. S., & Kumar, S. R. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5295-x · Cited by 30
Elvira-Torales, L. I., Martín‐Pozuelo, G., González‐Barrio, R., NAVARRO-GONZÁLEZ, I., Pallarés, F. J., Santaella, M., García‐Alonso, J., Sevilla, A., & Periago, M. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071662 · Cited by 30
“Non-alcoholic fatty liver disease (NAFLD) is the liver disease which is disseminated most widely around the world due to genetic, dietary, and lifestyle factors [1].”
BackgroundGonzález, D., & Sinha, J. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1881 · Cited by 31
Kord‐Varkaneh, H., Poursoleiman, F., Masri, M. K. A., Alras, K. A., Shayah, Y., Masmoum, M. D., Alangari, F. A., Alras, A., Rinaldi, G., Day, A. S., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.987921 · Cited by 33
“Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases worldwide (20–30%) (1).”
BackgroundMethodFast food diet with CCl4 micro-dose induced hepatic-fibrosis –a novel animal model
Chheda, T. K., Pratibha, S., Sadasivan, S. K., Chanderasekharan, H., Moolemath, Y., Oommen, A. M., Madanahalli, J. R., & Marikunte, V. V. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-89 · Cited by 31
“The current prevalence of NAFLD in the western world is ~20–30% of the population [3,4] and is expected to increase to >40% by 2030 [5], indicating the growing risk for individuals leading a sedentary lifestyle on a high-fat, high-carbohydrate, calorie-rich diet.”
BackgroundPrevalence and Correlates of Suspected Nonalcoholic Fatty Liver Disease in Chinese Children
Song, P., Yu, J., Wang, M., Chang, X., Wang, J., & An, L. (2017) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph14050465 · Cited by 29
“Evidence from population-based prevalence studies of pediatric NAFLD suggests that the prevalence of NAFLD ranges from 40 to 70% among obese children [15].”
BackgroundProcino, F., Misciagna, G., Veronese, N., Caruso, M. G., Chiloiro, M., Cisternino, A. M., Notarnicola, M., Bonfiglio, C., Bruno, I., Buongiorno, C., et al. (2019) · Liver International · doi:10.1111/liv.13970 · Cited by 30
El-Kabbany, Z. A., Hamza, R. T., Ismail, E. A. R., Elsharkawy, A. M., Yosry, A., Musa, S., Khalaf, M. A., Elgawesh, R. M., & Esmat, G. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001608 · Cited by 29
Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
Welch, R. D., Billon, C., Losby, M., Bedia‐Diaz, G., Fang, Y., Avdagic, A., Elgendy, B., Burris, T. P., & Griffett, K. (2022) · Metabolites · doi:10.3390/metabo12030238 · Cited by 28
Wang, H., Sit, W.-H., Tipoe, G. L., & Wan, J. M. (2014) · Food and Chemical Toxicology · doi:10.1016/j.fct.2014.09.002 · Cited by 28
Liu, J.-J., Chen, Y., Mo, Z., Tian, G., Tan, A., Gao, Y., Yang, X., Zhang, H., & Li, Z. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141019782 · Cited by 28
SIMG-Messina Hypertransaminasemia Study Group, Cacciola, I., Scoglio, R., Alibrandi, A., Squadrito, G., & Raimondo, G. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1535-2 · Cited by 28
“The vast majority of individuals with abnormal liver biochemistry had the evidence of metabolic syndrome, in accordance with data showing that NASH is the major cause of liver disease in western countries [18–23].”
ResultNguyen, V., Li, J., Gan, J., Cordero, P., Ray, S., Solis-Cuevas, A., Khatib, M., & Oben, J. A. (2017) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2017/4697194 · Cited by 28
Cabrera, D., Cabello‐Verrugio, C., Solís, N., Martín, D. S., Cofré, C., Pizarro, M., Arab, J. P., Ábrigo, J., Campos, F., Irigoyen, B., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051339 · Cited by 29
“NAFLD prevalence has increased during the last decades, currently representing 20–30% of the general population [6,7].”
BackgroundNyakudya, T. T., Mukwevho, E., Nkomozepi, P., & Erlwanger, K. H. (2018) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174418000259 · Cited by 29
“…response and activation of hepatic stellate cells resulting in fibrosis.7,8 NAFLD has a high global prevalence which is increasing.9 According to Bellentani et al.,10 the recent increase in the global prevalence of NAFLD ranges from 6.3–33% with an average of 20% of the population, depending…”
BackgroundInfluentialCarbohydrate but not fat is associated with elevated aminotransferases
Kwon, O. W., Jun, D. W., Lee, S. M., Lee, K. N., Lee, H. L., Lee, O. Y., Yoon, B. C., & Choi, H. S. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05061.x · Cited by 28
Cardoso, B. R., Tan, S., Daly, R. M., Via, J. D., Georgousopoulou, E. N., & George, E. S. (2021) · Journal of Nutrition · doi:10.1093/jn/nxab253 · Cited by 32
Flóres, Y. N., Amoon, A. T., Su, B., Velázquez‐Cruz, R., Ramírez‐Palacios, P., Salmerón, J., Rivera‐Paredez, B., Sinsheimer, J. S., Lusis, A. J., Huertas‐Vázquez, A., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01526-5 · Cited by 32
CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Cocciolillo, S., Parruti, G., & Marzio, L. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i7.496 · Cited by 27
Thomas, A., Klein, M. S., Stevens, A. P., Reinders, Y., Hellerbrand, C., Dettmer, K., Gronwald, W., Oefner, P. J., & Reinders, J. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2012.12.027 · Cited by 29
Ramanujam, V., Amutha, A., Anjana, R. M., Ranjit Unnikrishnan, I., Deepa, M., & Mohan, V. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0165 · Cited by 27
“Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease seen in the absence of secondary causes for hepatic fat accumulation with a wide histological spectrum ranging from simple hepatic steatosis to steatohepatitis, cirrhotic liver, and even hepatocellular carcinoma.(1,2) It is well recognized that NAFLD…”
Flóres, Y. N., Velázquez‐Cruz, R., Ramírez‐Palacios, P., Bañuelos, M., Zhang, Z., Yee, H. F., Chang, S., Canizales‐Quinteros, S., Quiterio, M., Cabrera-Álvarez, G., et al. (2016) · Molecular Biology Reports · doi:10.1007/s11033-016-4058-z · Cited by 27
“NAFLD is found in up to 80–90 % of obese adults, in 30–50 % of diabetics, and in up to 90 % of patients with hyperlipidemia [12].”
Chen, Q., Tang, H., Zha, Z., Yin, H., Wang, Y., Wang, Y., Li, H., & Yue, L. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.05.191 · Cited by 27
Brunt, E. M., Neuschwander‐Tetri, B. A., & Burt, A. D. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3398-8.00006-4 · Cited by 29
Nobakht, H., Mahmoudi, T., Sabzikarian, M., Tabaeian, S. P., Rezamand, G., Asadi, A., Farahani, H., Dabiri, R., Mansour‐Ghanaei, F., Maleki, I., et al. (2020) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.202000000-39 · Cited by 28
“3 Iran University of Medical Sciences, Colorectal Research Center, Tehran, Iran.”
BackgroundMethodInfluentialAlqahtani, S. A., Broering, D., Alghamdi, S. A., Bzeizi, K. I., Alhusseini, N. K., Alabbad, S. I., Albenmousa, A. H., Alfaris, N., Abaalkhail, F. A., & Al-hamoudi, W. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01828-z · Cited by 30
“The main risk factors for NAFLD are obesity, type 2 diabetes mellitus (T2DM), dyslipidemia, and insulin resistance [8].”
BackgroundZhai, T., Xu, W., Liu, Y., Qian, K., Xiong, Y., & Chen, Y. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2313641 · Cited by 30
Stähli, P., Becchetti, C., Martiartu, N. K., Berzigotti, A., Frenz, M., & Jaeger, M. (2023) · Communications Medicine · doi:10.1038/s43856-023-00409-3 · Cited by 26
Chabanova, E., Bille, D. S., Thisted, E., Holm, J., & Thomsen, H. S. (2011) · European Journal of Radiology · doi:10.1016/j.ejrad.2011.02.017 · Cited by 26
Hepatic function and the cardiometabolic syndrome
Wiernsperger, N. F. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s51145 · Cited by 32
la Tijera, F. H., & Servín-Caamaño, A. I. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i10.1297 · Cited by 29
Kanth, V. V. R., Sasikala, M., Sharma, M., Rao, P. N., & Reddy, D. N. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i20.827 · Cited by 26
Epidemiology of nonalcoholic fatty liver disease: A primer
Do, A., & Lim, J. K. (2016) · Clinical Liver Disease · doi:10.1002/cld.547 · Cited by 26
How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?
Mann, J. P., Semple, R. K., & Armstrong, M. J. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00145 · Cited by 32
Blackett, J. W., Verna, E. C., & Lebwohl, B. (2019) · Digestive Diseases · doi:10.1159/000502684 · Cited by 26
Al-Qudimat, A. R., Al‐Zoubi, R. M., Yassin, A. A., Alwani, M. M., Aboumarzouk, O. M., Al‐Rumaihi, K., Talib, R. A., & Ansari, A. A. (2021) · Arab Journal of Urology · doi:10.1080/2090598x.2021.1959261 · Cited by 29
Systems biology approaches for studying the pathogenesis of non-alcoholic fatty liver disease
Fisher, C., Kierzek, A. M., Plant, N. J., & Moore, J. B. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15070 · Cited by 26
Animal Models Correlating Immune Cells for the Development of NAFLD/NASH
Iyer, S., Upadhyay, P. K., Majumdar, S. S., & Nagarajan, P. (2015) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2015.06.004 · Cited by 26
Wu, J., Chen, C., Hu, X., Cai, X., Guan, Y., Hu, H., Wang, Q., Chen, X., Cai, B., & Jing, X. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.12.096 · Cited by 26
Dibba, P., Li, A. A., Cholankeril, G. T., Iqbal, U., Gadiparthi, C., Khan, M. A., Kim, D., & Ahmed, A. (2018) · Medicines · doi:10.3390/medicines5020047 · Cited by 25
“The prevalence of NAFLD ranges between 6% and 35% worldwide, with wide variations inclusive of high prevalence in Europe [4,7].”
BackgroundInfluentialMehta, R., Shaw, G. A., Masschelin, P. M., Felix, S. C., Otgonsuren, M., Baranova, A. V., Goodman, Z. D., & Younossi, Z. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199294 · Cited by 25
Differential capability of metabolic substrates to promote hepatocellular lipid accumulation
Hoang, N. A., Richter, F., Schubert, M., Lorkowski, S., Klotz, L., & Steinbrenner, H. (2018) · European Journal of Nutrition · doi:10.1007/s00394-018-1847-2 · Cited by 29
Glucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression
Nason, S. R., Kim, T., Antipenko, J. P., Finan, B., DiMarchi, R., Hunter, C. S., & Habegger, K. M. (2020) · Endocrinology · doi:10.1210/endocr/bqz013 · Cited by 26
Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist?
Khandelwal, R., Dassanayake, A. S., Conjeevaram, H. S., & Singh, S. P. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i9.1479 · Cited by 29
Fatty acid changes help to better understand regression of nonalcoholic fatty liver disease
Maciejewska, D., Drozd, A., Ossowski, P., Ryterska, K., Jamioł-Milc, D., Banaszczak, M., Raszeja-Wyszomirska, J., Kaczorowska, M., Sabinicz, A., & Stachowska, E. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.301 · Cited by 25
Du, R., Xue, J., Wang, H.-B., Zhang, Y., & Xie, M.-L. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.014 · Cited by 24
Thomas, A., Stevens, A. P., Klein, M. S., Hellerbrand, C., Dettmer, K., Gronwald, W., Oefner, P. J., & Reinders, J. (2012) · PROTEOMICS · doi:10.1002/pmic.201100628 · Cited by 25
“It is frequently associated with components of the metabolic syndrome, namely obesity, type 2 diabetes, hypertension, and dyslipidaemia [1].”
BackgroundNonalcoholic Fatty Liver Disease
Ko, J. S. (2010) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2010.56.1.6 · Cited by 25
Keating, S. E., Parker, H. M., Hickman, I. J., Gomersall, S. R., Wallen, M. P., Coombes, J. S., Macdonald, G. A., George, J., & Johnson, N. A. (2017) · Liver International · doi:10.1111/liv.13488 · Cited by 26
Zubajlo, R. E., Benjamin, A., Grajo, J. R., Kaliannan, K., Kang, J. X., Bhan, A. K., Thomenius, K. E., Anthony, B., Dhyani, M., & Samir, A. E. (2018) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2018.07.020 · Cited by 24
“NAFLD is the most common liver disease with an estimated one billion patients globally (Loomba and Sanyal 2013) with an estimated prevalence of 17-51% in the general population with even higher rates in western countries (Bellentani et al. 2010; Chalasani et al. 2012).”
BackgroundDalem, J. D. R.-V., Driessen, J. H. M., Burden, A. M., Stehouwer, C. D. A., Klungel, O. H., de Vries, F., & Brouwers, M. C. G. J. (2021) · Hepatology · doi:10.1002/hep.32012 · Cited by 25
Lee, K. J., Moon, J. S., Kim, N. Y., & Ko, J. S. (2021) · Pediatric Obesity · doi:10.1111/ijpo.12852 · Cited by 24
Almohawes, Z. N., El-kott, A. F., Morsy, K., Shati, A. A., El-Kenawy, A. E.-M., Khalifa, H. S., Elsaid, F. G., Abd-Lateif, A.-E.-K. M., Abu-zaiton, A. S., Ebealy, E. R., et al. (2022) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2021.2024578 · Cited by 26
“…fatty liver disease (NAFLD) is a growing liver disorder that affects about 30% of the global population and is presented by a wide spectrum of histological changes that range from simple steatosis, non-alcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC) (Bellentani et al. 2010).”
BackgroundZheng, L., Lü, Z., Ma, Y., Cui, P., Zhang, X., Gan, J., & Li, G. (2025) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.14188 · Cited by 23
“17-19 Hyperlipidemia is characterized by elevated serum glucose and triglyceride concentrations, decreased levels of HDL-C, hypertension, and central obesity.”
Wang, P., Shao, X., Bao, Y., Zhu, J., Chen, L., Zhang, L., Ma, X., & Zhong, X. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.10.009 · Cited by 26
The VDAC1-based R-Tf-D-LP4 Peptide as a Potential Treatment for Diabetes Mellitus
Pittala, S., Levy, I., De, S., Pandey, S. K., Melnikov, N., Hyman, T., & Shoshan‐Barmatz, V. (2020) · Cells · doi:10.3390/cells9020481 · Cited by 24
“NAFLD a ff ects 20 to 30 percent of the general population in various countries, is more prevalent in males than females [28], and is often associated with insulin resistance, obesity, and diabetes mellitus (DM).”
BackgroundCorrelation between income and non-alcoholic fatty liver disease in a Chinese population
Hu, W., Liu, Z., Hao, H., Yu, W., Wang, X., Shao, X., Wu, X., Wen, S., Fan, Y.-Q., & Ni, Y. (2020) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.07.1109 · Cited by 24
George, E. S., Georgousopoulou, E. N., Mellor, D. D., Chrysohoou, C. A., Pitsavos, C., & Panagiotakos, D. B. (2022) · Nutrients · doi:10.3390/nu14122367 · Cited by 23
“Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and is present in 20–30% of populations in developed nations [1].”
BackgroundPaediatric non-alcoholic fatty liver disease: a practical overview for non-specialists
Mann, J. P., Goonetilleke, R., & McKiernan, P. J. (2015) · Archives of Disease in Childhood · doi:10.1136/archdischild-2014-307985 · Cited by 27
Du, S., Wang, C., Wei, J., Li, C., Li, Y., Feng, R., & Sun, C. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.047 · Cited by 23
Kobashi-Margáin, R. A., Gutiérrez-Grobe, Y., Ponciano‐Rodríguez, G., Uribe, M., & Méndez‐Sánchez, N. (2010) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31638-2 · Cited by 23
Evaluation of atherosclerotic findings in patients with nonalcoholic fatty liver disease
Mohammadi, A., Bazazi, A., & Ghasemi-rad, M. (2011) · International Journal of General Medicine · doi:10.2147/ijgm.s25753 · Cited by 23
Shojaei‐Zarghani, S., Soraya, H., Zarei, L., & Alizadeh, M. (2016) · Pharmaceutical Sciences · doi:10.15171/ps.2016.03 · Cited by 25
Verhaegh, P., Wisse, E., de Munck, T., Greve, J. W., Verheij, J., Riedl, R., Duimel, H., Masclee, A., Jonkers, D., & Koek, G. (2021) · Pathology · doi:10.1016/j.pathol.2020.07.018 · Cited by 22
Chronic PET‐Microplastic Exposure: Disruption of Gut–Liver Homeostasis and Risk of Hepatic Steatosis
Park, S., Kim, M., Shin, J., Kim, E., Son, M., & Lee, S. (2025) · Advanced Science · doi:10.1002/advs.202512030 · Cited by 34
“Weighing the risk”: Obesity and outcomes following liver transplantation
Reichman, T., Therapondos, G., Serrano, M.-S., Seal, J., Evers-Meltzer, R., Bohorquez, H., Cohen, A., Carmody, I., Ahmed, E., Bruce, D., et al. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i11.1484 · Cited by 27
Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis
Seen, T., Sayed, M. A., Bilal, M., Reyes, J. V. M., Bhandari, P., Lourdusamy, V., Al‐Khazraji, A., Syed, U. M., Sattar, Y., & Bansal, R. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i23.3238 · Cited by 22
Tung, T., Chang, T.-H., Chiu, W., Lin, T.-H., Shih, H., Chang, M.-H., & Liu, J. (2011) · BMC Research Notes · doi:10.1186/1756-0500-4-315 · Cited by 22
Automated quantification of ultrasonic fatty liver texture based on curvelet transform and SVD
Bharath, R., Mishra, P. K., & Rajalakshmi, P. (2017) · Journal of Applied Biomedicine · doi:10.1016/j.bbe.2017.12.004 · Cited by 24
Epigenetics: An emerging field in the pathogenesis of nonalcoholic fatty liver disease
Ashraf, N. U., & Altaf, M. (2018) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2018.07.002 · Cited by 30
Application of Magnetic Resonance Spectroscopy in metabolic research
van de Weijer, T., & Schrauwen‐Hinderling, V. B. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.09.013 · Cited by 25
Global Epidemiology of Chronic Liver Disease
Ladep, N. G., Akbar, S. M. F., & Mahtab, M. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-94355-8_5 · Cited by 23
The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma
Sherif, Z. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85780 · Cited by 27
Hydrogen peroxide impairs autophagic flux in a cell model of nonalcoholic fatty liver disease
Jiang, P., Huang, Z., Zhao, H. C., & Wei, T. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.02.118 · Cited by 22
Zhang, Y., Li, F., Jiang, X., Jiang, X., Wang, Y., Zhang, H., Zhang, L. R., Fan, S., Xin, L., Yang, B., et al. (2020) · Phytotherapy Research · doi:10.1002/ptr.6747 · Cited by 24
Metadata
- Authors
- Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G.
- Venue
- Digestive Diseases
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 28
- Issue
- 1
- Pages
- 155-161
- ISSN
- 0257-2753 (ISSN-L)
- 1421-9875
- OpenAlex
- W2036047239
- Cited by
- 1,026
- References
- 77
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 31 · 2023: 51 · 2022: 72 · 2021: 71 · 2020: 78 · 2019: 85 · 2018: 96 · 2017: 97 · 2016: 89 · 2015: 84 · 2014: 71 · 2013: 81 · 2012: 48
- FWCI
- 40.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Digestive Diseases (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, prevalence, nonalcoholic steatohepatitis, liver cirrhosis, hepatocellular carcinoma, risk factors, obesity, insulin resistance, metabolic syndrome, fatty liver index, NAFLD screening, pediatric NAFLD, incidence, lifestyle, transaminases
- MeSH terms
- Adult, Aged, Fatty Liver, Female, Humans, Italy, Male, Middle Aged, Risk Factors, United States, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.